Search for content, post, videos

LEO Pharma appoints EVP Global Research and Development

Joerg Moeller

LEO Pharma has announced that Joerg Moeller will join its Global Leadership Team as Executive Vice President, Global Research and Development.

Moeller joins LEO Pharma from Bayer Pharma, where he has been EVP Head of R&D and Member of the Bayer Pharma Executive Committee.

“Joerg Moeller’s experience will help us to significantly foster our innovative pipeline which underpins our ambition to become a global leader in medical dermatology,” says Catherine Mazzacco, President and CEO of LEO Pharma.

Experience from a long international career

A medical doctor and Ph.D. by training, Joerg Moeller brings a wealth of experience from his long international career during which he was responsible for a significant global organization with main hubs in Germany, the US, Switzerland, Japan and China, states LEO Pharma. He led the entire value chain from target and drug discovery through clinical development, life-cycle-management and regulatory approvals and has brought a range of successful global product approvals. His experience spans multiple therapeutic areas including dermatology and immunology and a variety of technology platforms like biologics and cell & gene therapies. He has a solid track record of working with external partners, the company states.

“I am excited to join LEO Pharma and inspired by its strategy and ambition. People with dermatologic medical conditions need new treatment options, and I want to bring in my experience and expertise to the R&D team at LEO Pharma so we together can contribute significantly to improving patients’ lives,” says Joerg Moeller.

Joerg Moeller succeeds Kim Kjøller who decided to leave LEO Pharma for a CEO role at Union Therapeutics.

Photo of Joerg Moeller: Bayer